Sanofi (SNY) — Stock Price, Chart & Analysis
Sanofi (SNY) is a Healthcare stock currently trading at $100, up 0.00% on the day. It carries a market capitalization of $104.14B and a trailing P/E ratio of 22.87. Over the past 52 weeks, SNY has traded between $40.89 and $52.68. Sanofi pays a dividend yielding 5.6%. View the live SNY chart, technical opinion, analyst ratings, fundamentals and latest news below.
Sanofi (SNY) key data
| Price | $100 |
| Change (today) | +0.00% |
| Previous close | $100 |
| Market cap | $104.14B |
| P/E ratio (TTM) | 22.87 |
| EPS (TTM) | $1.90 |
| Dividend yield | 5.6% |
| 52-week high | $52.68 |
| 52-week low | $40.89 |
| Beta | 0.28 |
| Avg. volume | 3.44M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Frequently asked questions about Sanofi (SNY)
How much does one share of Sanofi cost?
As of the latest update, one share of Sanofi (SNY) trades at $100 (+0.00% today).
What is Sanofi's market cap?
Sanofi has a market capitalization of approximately $104.14B.
What is Sanofi's P/E ratio?
Sanofi has a trailing price-to-earnings (P/E) ratio of 22.87.
What is Sanofi's earnings per share (EPS)?
Sanofi's trailing twelve-month EPS is $1.90.
Does Sanofi pay a dividend?
Yes — Sanofi pays a dividend with a yield of 5.6% ($2.42 per share annually).
What is Sanofi's 52-week trading range?
Over the past year, SNY has traded between $40.89 and $52.68.
What is the analyst price target for Sanofi?
The mean analyst price target for Sanofi is $54.06. This is informational only and not investment advice.
Latest Sanofi (SNY) news
- Global Influenza Vaccine Market Report, 2026 Edition - Profiles GlaxoSmithKline, Pfizer, Sanofi, Moderna, and 9 Other PlayersNews · Aug 7, 2026
- Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOsNews · Jul 31, 2026
- Leap Expands Manufacturer & Specialty Network Partnerships with Appointment of Industry Executive Christine HummelNews · Aug 6, 2026
- NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook RaisedNews · Aug 7, 2026
- Novavax Q2 Earnings Call HighlightsNews · Aug 7, 2026
- NVAX Stock Holds Steady As Novavax Lifts Revenue Outlook On Licensing Pivot — Retail Eyes Buyout, More Partnership DealsNews · Aug 6, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live SNY dashboard…